Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 18, 2008 - Issue 7
Submit an article Journal homepage
67
Views
1
CrossRef citations to date
0
Altmetric
Review

Nerve growth factor and brain-derived neurotrophic factor: potential targets for migraine treatment?

Paola Sarchielli Neurologic Clinic, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, 06156 Perugia, Italy +39 075 578 3609; +39 075 578 4229; [email protected]
, MD,
Katiuscia Nardi Neurologic Clinic, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, 06156 Perugia, Italy +39 075 578 3609; +39 075 578 4229; [email protected]
, MD,
Maria Luisa Mancini Neurologic Clinic, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, 06156 Perugia, Italy +39 075 578 3609; +39 075 578 4229; [email protected]
, MD,
Ilenia Corbelli Neurologic Clinic, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, 06156 Perugia, Italy +39 075 578 3609; +39 075 578 4229; [email protected]
, MD,
Nicola Tambasco Neurologic Clinic, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, 06156 Perugia, Italy +39 075 578 3609; +39 075 578 4229; [email protected]
, MD,
Davide Chiasserini Neurologic Clinic, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, 06156 Perugia, Italy +39 075 578 3609; +39 075 578 4229; [email protected]; University of Perugia, Department of Internal Medicine section of Biochemistry, Perugia, Italy
, MD &
Paolo Calabresi Neurologic Clinic, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, 06156 Perugia, Italy +39 075 578 3609; +39 075 578 4229; [email protected]; I.R.C.C.S, Fondazione Santa Lucia, Rome, Italy
, MD show all
Pages 705-721 | Published online: 19 Jun 2008

Bibliography

  • Allen SJ, Dawbarn D. Clinical relevance of the neurotrophins and their receptors. Clin Sci 2006;110:175-91
  • Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Ann Rev Neurosci 2006;29:507-38
  • Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Ann Rev Biochem 2003;72:609-42
  • Gentry JJ, Barker PA, Carter BD. The p75 neurotrophin receptor: multiple interactors and numerous functions. Prog Brain Res 2004;146:25-39
  • Reichardt LF. Neurotrophin-regulated signalling pathways. Phil Trans R Soc B 2006;361:1545-64
  • Merighi A, Carmignoto G, Gobbo S, et al. Neurotrophins in spinal cord nociceptive pathways. Prog Brain Res 2004;146:291-321
  • Pezet S, Malcangio M, McMahon SB. BDNF: a neuromodulator in nociceptive pathways? Brain Res Brain Res Rev 2002;40:240-9
  • Sarchielli P, Alberti A, Floridi A, Gallai V. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology 2001;57:132-4
  • Sarchielli P, Alberti A, Gallai B, et al. Brain-derived neurotrophic factor in cerebrospinal fluid of patients with chronic daily headache: relationship with nerve growth factor and glutamate levels. J Headache Pain 2002;3:129-35
  • Sarchielli P, Mancini ML, Floridi A, et al. Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain 2007;8:737-45
  • Jacobs JS, Miller MW. Expression of nerve growth factor, p75, and the high affinity neurotrophin receptors in the adult rat trigeminal system: evidence for multiple trophic support systems. J Neurocytol 1999;28:571-95
  • Ichikawa H, Yabuuchi T, Jin HW, et al. Brain-derived neurotrophic factor-immunoreactive primary sensory neurons in the rat trigeminal ganglion and trigeminal sensory nuclei. Brain Res 2006;1081:113-8
  • Mosconi T, Snider WD, Jacquin MF. Neurotrophin receptor expression in retrogradely labeled trigeminal nociceptors: comparisons with spinal nociceptors. Somatosens Mot Res 2001;18:312-21
  • Quartu M, Geic M, Del Fiacco M. Neurotrophin-like immunoreactivity in the human trigeminal ganglion. Neuroreport 1997;8:3611-7
  • Zhou XF, Song XY, Zhong JH, et al. Distribution and localization of pro-brain-derived neurotrophic factor-like immunoreactivity in the peripheral and central nervous system of the adult rat. J Neurochem 2004;91:704-15
  • Quartu M, Setzu MD, Del Fiacco M. Trk-like immunoreactivity in the human trigeminal ganglion and subnucleus caudalis. Neuroreport 1996;7:1013-9
  • Krol KM, Stein EJ, Elliott J, Kawaja MD. TrkA-expressing trigeminal sensory neurons display both neurochemical and structural plasticity despite a loss of p75NTR function: responses to normal and elevated levels of nerve growth factor. Eur J Neurosci 2001;13:35-47
  • Behnia A, Zhang L, Charles M, Gold MS. Changes in TrkB-like immunoreactivity in rat trigeminal ganglion after tooth injury. J Endod 2003;29:135-40
  • FrisÉn J, Risling M, Korhonen L, et al. Nerve growth factor induces process formation in meningeal cells: implications for scar formation in the injured CNS. J Neurosci 1998;18:5714-22
  • King VR, Michael GJ, Joshi RK, Priestley JV. TrkA, TrkB, and TrkC messenger RNA expression by bulbospinal cells of the rat. Neuroscience 1999;92:935-44
  • Slack SE, Grist J, Mac Q, et al. TrkB expression and phospho-ERK activation by brain-derived neurotrophic factor in rat spinothalamic tract neurons. J Comp Neurol 2005;489:59-68
  • Spears R, Dees LA, Sapozhnikov M, et al. Temporal changes in inflammatory mediator concentrations in an adjuvant model of temporomandibular joint inflammation. J Orofac Pain 2005;19:34-40
  • Price TJ, Louria MD, Candelario-Soto D, et al. Treatment of trigeminal ganglion neurons in vitro with NGF, GDNF or BDNF: effects on neuronal survival, neurochemical properties and TRPV1-mediated neuropeptide secretion. BMC Neurosci 2005;6:4
  • Durham PL, Russo AF. Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons. J Neurosci 2003;23:807-15
  • Simonetti M, Fabbro A, D'Arco M, et al. Comparison of P2X and TRPV1 receptors in ganglia or primary culture of trigeminal neurons and their modulation by NGF or serotonin. Mol Pain 2006;2:11
  • Diogenes A, Akopian AN, Hargreaves KM. NGF up-regulates TRPA1: implications for orofacial pain. Dent Res 2007;86:550-5
  • D'Arco M, Giniatullin R, Simonetti M, et al. Neutralization of nerve growth factor induces plasticity of ATP-sensitive P2X3 receptors of nociceptive trigeminal ganglion neurons. J Neurosci 2007;27:8190-201
  • Wheeler EF, Naftel JP, Pan M, et al. Neurotrophin receptor expression is induced in a subpopulation of trigeminal neurons that label by retrograde transport of NGF or fluoro-gold following tooth injury. Brain Res Mol Brain Res 1998;61:23-38
  • Michael GJ, Averill S, Nitkunan A, et al. Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J Neurosci 1997;17:8476-90
  • Buldyrev I, Tanner NM, Hsieh HY, et al. Calcitonin gene-related peptide enhances release of native brain-derived neurotrophic factor from trigeminal ganglion neurons. J Neurochem 2006;99:1338-50
  • Obata K, Noguchi K. BDNF in sensory neurons and chronic pain. Neurosci Res 2006;55:1-10
  • Malick A, Burstein R. Peripheral and central sensitization during migraine. Funct Neurol 2000;15:28-35
  • Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998;79:964-82
  • Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000;123:1703-9
  • Bendtsen L. Sensitization: its role in primary headache. Curr Opin Investig Drugs 2002;3:449-53
  • Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001;89:107-10
  • Deleo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 2001;90:1-6
  • Kawamoto K, Aoki J, Tanaka A, et al. Nerve growth factor activates mast cells through the collaborative interaction with lysophosphatidylserine expressed on the membrane surface of activated platelets. J Immunol 2002;168:6412-9
  • Reuter U, Bolay H, Jansen-Olesen I, et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 2001;124:2490-502
  • Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002;51:507-16
  • Sarchielli P, Alberti A, Baldi A, et al. Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache 2006;46:200-7
  • Sarchielli P, Floridi A, Mancini ML, et al. NF-kappaB activity and iNOS expression in monocytes from internal jugular blood of migraine without aura patients during attacks. Cephalalgia 2006;26:1071-9
  • Sarchielli P, Alberti A, Coppola F, et al. Platelet-activating factor (PAF) in internal jugular venous blood of migraine without aura patients assessed during migraine attacks. Cephalalgia 2004;24:623-30
  • Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain 2007;131:243-57
  • Padilla F, Couble ML, Coste B, et al. Expression and localization of the Nav1.9 sodium channel in enteric neurons and in trigeminal sensory endings: implication for intestinal reflex function and orofacial pain. Mol Cell Neurosci 2007;35:138-52
  • Fabbretti E, D'arco M, Fabbro A, et al. Delayed upregulation of ATP P2X3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide. J Neurosci 2006;26:6163-71
  • Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia 2004;24:2-7
  • Bolton S, O'shaughnessy CT, Goadsby PJ. Properties of neurons in the trigeminal nucleus caudalis responding to noxious dural and facial stimulation. Brain Res 2005;1046:122-9
  • Onodera K, Hamba M, Takahashi T. Primary afferent synaptic responses recorded from trigeminal caudal neurons in a mandibular nerve-brainstem preparation of neonatal rats. J Physiol 2000;524:503-12
  • Sarchielli P, Di Filippo M, Nardi K, Calabresi P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep 2007;11:343-51
  • Vikelis M, Mitsikostas DD. The role of glutamate and its receptors in migraine. CNS Neurol Disord Drug Targets 2007;6:251-7
  • Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614-24
  • Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine: implications for treatment. CNS Drugs 2004;18:337-42
  • Ashkenazi A, Sholtzow M, Shaw JW, et al. Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia 2007;27:111-7
  • Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors 2004;22:123-31
  • Carvalho AL, Caldeira MV, Santos SD, Duarte CB. Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol 2008;153:S310-24
  • Xu L, Mabuchi T, Katano T, et al. Nitric oxide (NO) serves as a retrograde messenger to activate neuronal NO synthase in the spinal cord via NMDA receptors. Nitric Oxide 2007;17:18-24
  • Lessmann V. Neurotrophin-dependent modulation of glutamatergic synaptic transmission in the mammalian CNS. Gen Pharmacol 1998;31:667-74
  • Guo W, Robbins MT, Wei F, et al. Supraspinal brain-derived neurotrophic factor signaling: a novel mechanism for descending pain facilitation. J Neurosci 2006;26:126-37
  • Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd edition. Cephalalgia 2004;24:9-160
  • Blandini F, Rinaldi L, Tassorelli C, et al. Peripheral levels of BDNF and NGF in primary headache. Cephalalgia 2006;26:136-42
  • Vogler B, Rapoport AM, Tepper SJ, et al. Role of melatonin in the pathophysiology of migraine: implications for treatment. CNS Drugs 2006;20:343-50
  • Kong X, Li X, Cai Z, et al. Melatonin regulates the viability and differentiation of rat midbrain neural stem cells. Cell Mol Neurobiol 2008;28:569-79
  • Niles LP, Armstrong KJ, Rincón Castro LM, et al. Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers. BMC Neurosci 2004;5:41
  • Pongsa-Asawapaiboon A, Asavaritikrai P, Withyachumnarnkul B, Sumridthong A. Melatonin increases nerve growth factor in mouse submandibular gland. J Pineal Res 1998;24:73-7
  • Saragovi HU, Gehring K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol Sci 2000;21:93-8
  • Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006;27:85-91
  • Salter MW. Cellular signalling pathways of spinal pain neuroplasticity as targets for analgesic development. Curr Top Med Chem 2005;5:557-67
  • Koltzenburg M, Bennett DL, Shelton DL, McMahon SB. Neutralization of endogenous NGF prevents the sensitization of nociceptors supplying inflamed skin. Eur J Neurosci 1999;11:1698-704
  • Gwak YS, Nam TS, Paik KS, et al. Attenuation of mechanical hyperalgesia following spinal cord injury by administration of antibodies to nerve growth factor in the rat. Neurosci Lett 2003;336:117-20
  • Wild KD, Bian D, Zhu D, et al. Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance. J Pharmacol Exp Ther 2007;322:282-7
  • Ro LS, Chen ST, Tang LM, Jacobs JM. Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction injury of the sciatic nerve. Pain 1999;79:265-74
  • McMahon SB. NGF as a mediator of inflammatory pain. Phil Trans R Soc Lond B Biol Sci 1996;351:431-40
  • Christensen MD, Hulsebosch CE. Spinal cord injury and anti-NGF treatment results in changes in CGRP density and distribution in the dorsal horn in the rat. Exp Neurol 1997;147:463-75
  • Chudler EH, Anderson LC, Byers MR. Nerve growth factor depletion by autoimmunization produces thermal hypoalgesia in adult rats. Brain Res 1997;765:327-30
  • Halvorson KG, Kubota K, Sevcik MA, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005;65:9426-35
  • Jimenez-Andrade JM, Martin CD, Koewler NJ, et al. Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. Pain 2007;133:183-96
  • Diop L, Delafoy L. Use of NGF-antagonists for the prevention or treatment of chronic visceral pain. WO0178698; 2001
  • Clark M. Antibody humanization: a case of the ‘Emperor's new clothes’? Immunol Today 2000;21:397-402
  • Wild KD, Treanor JJ, Huang H, et al. Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors. US2008033157; 2008, WO2005019266; 2005
  • Shelton DL, Mantyh PW. Methods for treating bone cancer pain by administering a nerve growth factor antagonist. CN101023099; 2007
  • Shelton DL, Mantyh PW. Methods for treating bone cancer pain by administering a nerve growth factor antagonist. WO2005111077; 2005
  • Shelton DL, Vergara GJ. Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same. WO2004032870; 2004
  • Shelton DL, Vergara GJ. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody. US2007160605; 2007
  • Rosenthal A, Shelton DL, Walicke PA. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same. WO2006110883; 2006
  • Shelton DL, Vergara GJ. Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same. WO2004096122; 2004
  • Longo FM, Mobley WC, Kauer JC. Nerve growth factor peptides. WO8909225; 1989
  • Riopelle RJ, Ross GM, Dory MI, et al. Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity. WO9715593; 1997, US6291247; 2001
  • Ross GM, Shamovsky IL, Marone S, et al. Method of inhibiting neurotrophin receptor binding. WO0069829; 2000
  • Gingrich DE, Hudkins RL. Fused pyrrolocarbazoles against inflammation. WO0217914; 2002
  • Kuyper LF, Lackey KE, Wood ER. Substituted oxindole derivatives as tyrosine kinase inhibitors. WO0220479; 2002
  • Singh J, Hudkins RL, Mallamo JP, et al. Bridged indenopyrrolocarbazoles. US6127401; 2000, US6359130; 2002
  • Pesavento E, Margotti E, Righi M, et al. Blocking the NGF-TrkA interaction rescues the developmental loss of LTP in the rat visual cortex: role of the cholinergic system. Neuron 2000;25:165-75
  • Saragovi HU, Lesauteur L, Cuello C. Nerve growth factor structural analogs and their uses. US6017878; 2001
  • Lesauteur L, Wei L, Gibbs BF, Saragovi HU. Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses. J Biol Chem 1995;270:6564-9
  • Colquhoun A, Lawrance GM, Shamovsky IL, et al. Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzolylamino)-4,9-dihydro-4-methyl-9-oxo-pyrazolo[5,1-b]quinazoline-2-carboxylic acid] suggests altered NGF-p75NTR interactions in the presence of TrkA. J Pharmacol Exp Ther 2004;310:505-11
  • Spiegel K, Agrafiotis D, Caprathe B, et al. PD 90780, a non peptide inhibitor of nerve growth factor's binding to the P75 NGF receptor. Biochem Biophys Res Commun 1995;217:488-94
  • Jaen JC, Laborde E, Bucsh RA, et al. Kynurenic acid derivatives inhibit the binding of nerve growth factor (NGF) to the low-affinity p75 NGF receptor. J Med Chem 1995;38:4439-45
  • Owolabi JB, Rizkalla G, Tehim A, et al. Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. J Pharmacol Exp Ther 1999;289:1271-6
  • Woolf NJ, Milov AM, Schweitzer ES, Roghani A. Elevation of nerve growth factor and antisense knockdown of TrkA receptor during contextual memory consolidation. J Neurosci 2001;21:1047-55
  • Yamashita T, Watanabe T. Analgesic agent comprising p75-NTR inhibitor as active ingredient. WO2007026567; 2007
  • Cattaneo A, Capsoni S, Margotti E, et al. Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody. J Neurosci 1999;19:9687-97
  • Ugolini G, Marinelli S, Covaceuszach S, et al. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc Natl Acad Sci USA 2007;104:2985-90
  • Covaceuszach S, Cattaneo A, Lamba D. Purification, crystallization and preliminary X-ray analysis of the Fab fragment from MNAC13, a novel antagonistic anti-tyrosine kinase A receptor monoclonal antibody. Acta Crystallogr D Biol Crystallogr 2001;57:1307-9
  • Covaceuszach S, Cattaneo A, Lamba D. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight. Proteins 2005;58:717-27
  • Pavone F, Martinelli S, Cattaneo A, Ugolini G. Novel analgesic treatment with prolonged effect. WO2006131952; 2006
  • Pavone F, Martinelli S, Cattaneo A, Ugolini G. Method for the potentiation of opioid analgesics effects on pain. WO2006137106; 006
  • Presta LG, Shelton DL, Urfer R. Human TRK receptors and neurotrophic factor inhibitors. US2002146416; 2002, US2003157099; 2003, US2004058416; 2004
  • Dawbarn D, Fahey M, Watson J, et al. NGF receptor TrkAd5: therapeutic agent and drug design target. Biochem Soc Trans 2006;34:587-90
  • Jiang JB, Johnson MG. 1,4-Bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase C. US5141957; 1992, US5204370; 1993, US5216014; 1993, US5344841; 1994
  • Bell RM, Fogelsong RJ, Nichols JB. N-aminoalkyl amide inhibitors of protein kinase C. US5270310; 1993
  • Jiang JB, Johnson MG, Nichols J. 1,3-Dioxane derivatives having protein kinase C inhibitory activity. US5360818; 1994
  • Khasar SG, Lin YH, Martin A, et al. A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice. Neuron 1999;24:253-60
  • Messing RO, Levine JD. Use of inhibitors of protein kinase C epsilon to treat pain. US2002151465; 2002
  • Kerr BJ, Bradbury EJ, Bennett DL, et al. Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. J Neurosci 1999;19:5138-48
  • Yajima Y, Narita M, Narita M, et al. Involvement of a spinal brain-derived neurotrophic factor/full-length TrkB pathway in the development of nerve injury-induced thermal hyperalgesia in mice. Brain Res 2002;958:338-46
  • QuintÃo NL, Santos AR, Campos MM, Calixto JB. The role of neurotrophic factors in genesis and maintenance of mechanical hypernociception after brachial plexus avulsion in mice. Pain 2008;136:125-33
  • Marcol W, Kotulska K, Larysz-Brysz M, Kowalik JL. BDNF contributes to animal model neuropathic pain after peripheral nerve transection. Neurosurg Rev 2007;30:235-43
  • Ji RR, Baba H, Brenner GJ, Woolf CJ. Nociceptive-specific activation of ERK in spinal neuons contributes to pain hypersensitivity. Nat Neurosci 1999;2:1114-9
  • Yajima Y, Narita M, Usui A, et al. Direct evidence for the involvement of brain-derived neurotrophic factor in the development of a neuropathic pain-like state in mice. J Neurochem 2005;93:584-47
  • Molnar M, Tongiorgi E, Avignone E, et al. The effects of anti-nerve growth factor monoclonal antibodies on developing basal forebrain neurons are transient and reversible. Eur J Neurosci 1998;10:3127-40
  • Niewiadomska G, Komorowski S, Baksalerska-Pazera M. Amelioration of cholinergic neurons dysfunction in aged rats depends on the continuous supply of NGF. Neurobiol Aging 2002;23:601-13
  • Lu VB, Ballanyi K, Colmers WF, Smith PA. Neuron type-specific effects of brain-derived neurotrophic factor in rat superficial dorsal horn and their relevance to ‘central sensitization’. J Physiol 2007;584:543-63
  • Coull J, De Koninck Y, Salter M, Beggs S. Modulation of neuroglia-derived BDNF in the treatment and prevention of pain. WO2006042396; 2006, CN101060863; 2007
  • Skaper SD. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 2008;7:46-62
  • Pesavento E, Capsoni S, Domenici L, Cattaneo A. Acute cholinergic rescue of synaptic plasticity in the neurodegenerating cortex of anti-nerve-growth-factor mice. Eur J Neurosci 2002;15:1030-6
  • Cuello AC, Bruno MA, Bell KF. NGF-cholinergic dependency in brain aging, MCI and Alzheimer's disease. Curr Alzheimer Res 2007;4:351-8
  • Lewin GR, Winter J, McMahon SB. Regulation of afferent connectivity in the adult spinal cord by nerve growth factor. Eur J Neurosci 1992;4:700-7
  • Wolff JR, Missler M. Synaptic remodelling and elimination as integral processes of synaptogenesis. APMIS Suppl 1993;40:9-23
  • Miller MW. Expression of nerve growth factor and its receptors in the somatosensory-motor cortex of Macaca nemestrina. J Neurocytol 2000;29:453-69
  • Lindholm D, CastrÉn E, Berzaghi M, et al. Activity-dependent and hormonal regulation of neurotrophin mRNA levels in the brain: implications for neuronal plasticity. J Neurobiol 1994;25:1362-72
  • Debeir T, Saragovi HU, Cuello AC. TrkA antagonists decrease NGF-induced ChAT activity in vitro and modulate cholinergic synaptic number in vivo. J Physiol (Paris) 1998;92:205-8
  • Summer GJ, Puntillo KA, Miaskowski C, et al. TrkA and PKC-epsilon in thermal burn-induced mechanical hyperalgesia in the rat. J Pain 2006;7:884-91
  • Kim HM, Hirota S, Chung HT, et al. PKC gamma gene expression is delayed in postnatal central nervous system of mi/mi mice. J Mol Neurosci 1993;4:245-53
  • Pezet S, Cunningham J, Patel J, et al. BDNF modulates sensory neuron synaptic activity by a facilitation of GABA transmission in the dorsal horn. Cell Neurosci 2002;21:51-62
  • Groth R, Aanonsen L. Spinal brain-derived neurotrophic factor (BDNF) produces hyperalgesia in normal mice while antisense directed against either BDNF or trkB, prevent inflammation-induced hyperalgesia. Pain 2002;100:171-81

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.